{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:06:42Z","timestamp":1779293202923,"version":"3.51.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Health Commission Scientific Research Program of Chongqing","award":["2012-2-056"],"award-info":[{"award-number":["2012-2-056"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Immunotherapy is a vital component in cancer treatment. However, due to the complex genetic bases of cancer, a clear prediction index for efficacy has not been established. Tumor mutation burden (TMB) is one of the essential factors that affect immunotherapeutic efficacies, but it has not been determined whether the mutation is associated with the survival of Skin Cutaneous Melanoma (SKCM) patients. This study aimed at evaluating the correlation between TMB and immune infiltration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Somatic mutation profiles (<jats:italic>n<\/jats:italic>\u2009=\u2009467), transcriptome data (<jats:italic>n<\/jats:italic>\u2009=\u2009471), and their clinical information (<jats:italic>n<\/jats:italic>\u2009=\u2009447) of all SKCM samples were downloaded from The Cancer Genome Atlas (TCGA) database. For each sample, TMB was calculated as the number of variants per megabase. Based on K-M survival analysis, they were allocated into the high-TMB and low-TMB groups (the optimal cutoff was determined by the \u2018surv_cutpoint\u2019 algorithm of survival R package). Then, Gene ontology (GO) and Gene Set Enrichment Analyses (GSEA) were performed, with immune-associated biological pathways found to be significantly enriched in the low-TMB group. Therefore, immune genes that were differentially expressed between the two groups were evaluated in Cox regression to determine their prognostic values, and a four-gene TMB immune prognostic model (TMB-IP) was constructed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Elevated TMB levels were associated with better survival outcomes in SKCM patients. Based on the cutoff value in OS analysis, they were divided into high-TMB and low-TMB groups. GSEA revealed that the low-TMB group was associated with immunity while intersection analysis revealed that there were 38 differentially expressed immune-related genes between the two groups. Four TMB-associated immune genes were used to construct a TMB-IP model. The AUC of the ROC curve of this model reached a maximum of 0.75 (95%CI, 0.66\u20130.85) for OS outcomes. Validation in each clinical subgroup confirmed the efficacy of the model to distinguish between high and low TMB-IP score patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In SKCM patients, low TMB was associated with worse survival outcomes and enriched immune-associated pathways. The four TMB-associated immune genes model can effectively distinguish between high and low-risk patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-08083-1","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T08:09:23Z","timestamp":1617955763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Gene expression and immune infiltration in melanoma patients with different mutation burden"],"prefix":"10.1186","volume":"21","author":[{"given":"Liwei","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guosheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9290-4490","authenticated-orcid":false,"given":"Zhengjian","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"8083_CR1","doi-asserted-by":"crossref","unstructured":"De La Cruz MM, Abdul Z, Shariff Z. The impact of a skin cancer diagnosis on travel insurance: a sun worshipper's dilemma. Clin Exp Dermatol. 2020.","DOI":"10.1111\/ced.14505"},{"key":"8083_CR2","doi-asserted-by":"crossref","unstructured":"Siegel JA, Yudkin JS, Craker K, Hwang A, Libby T. Uncapping the bottle: a proposal to allow full-sized sunscreens in carry-on luggage to promote sun protection and prevent skin cancer. J Am Acad Dermatol. 2020.","DOI":"10.1016\/j.jaad.2020.10.066"},{"issue":"5","key":"8083_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/em.22176","volume":"59","author":"AQ Khan","year":"2018","unstructured":"Khan AQ, Travers JB, Kemp MG. Roles of UVA radiation and DNA damage responses in melanoma pathogenesis. Environ Mol Mutagen. 2018;59(5):438\u201360. https:\/\/doi.org\/10.1002\/em.22176.","journal-title":"Environ Mol Mutagen"},{"key":"8083_CR4","doi-asserted-by":"crossref","unstructured":"Gupta R, Janostiak R, Wajapeyee N. Transcriptional regulators and alterations that drive melanoma initiation and progression. ONCOGENE. 2020;39(48):7093\u2013105.","DOI":"10.1038\/s41388-020-01490-x"},{"issue":"6","key":"8083_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"8083_CR6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"8083_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","volume":"66","author":"W Chen","year":"2016","unstructured":"Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115\u201332.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"8083_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","volume":"14","author":"JJ Luke","year":"2017","unstructured":"Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nat Rev Clin Oncol. 2017;14(8):463\u201382. https:\/\/doi.org\/10.1038\/nrclinonc.2017.43.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"8083_CR9","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S1470-2045(17)30171-7","volume":"18","author":"M Schreuer","year":"2017","unstructured":"Schreuer M, Jansen Y, Planken S, Chevolet I, Seremet T, Kruse V, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-Centre, phase 2 clinical trial. Lancet Oncol. 2017;18(4):464\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(17)30171-7.","journal-title":"Lancet Oncol"},{"issue":"19","key":"8083_CR10","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","volume":"377","author":"GV Long","year":"2017","unstructured":"Long GV, Hauschild A, Santinami M, Atkinson V, Mandal\u00e0 M, Chiarion-Sileni V, et al. Adjuvant Dabrafenib plus Trametinib in stage III BRAF-mutated melanoma. New Engl J Med. 2017;377(19):1813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa1708539.","journal-title":"New Engl J Med."},{"issue":"14","key":"8083_CR11","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1158\/1078-0432.CCR-17-1914","volume":"24","author":"M Sanlorenzo","year":"2018","unstructured":"Sanlorenzo M, Vujic I, Floris A, Novelli M, Gammaitoni L, Giraudo L, et al. BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti\u2013PD-1 antibody. Clin Cancer Res. 2018;24(14):3377\u201385. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-1914.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8083_CR12","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10555-017-9657-1","volume":"36","author":"M Kunz","year":"2017","unstructured":"Kunz M, H\u00f6lzel M. The impact of melanoma genetics on treatment response and resistance in clinical and experimental studies. Cancer Metast Rev. 2017;36(1):53\u201375. https:\/\/doi.org\/10.1007\/s10555-017-9657-1.","journal-title":"Cancer Metast Rev"},{"issue":"279","key":"8083_CR13","doi-asserted-by":"publisher","first-page":"241r","DOI":"10.1126\/scitranslmed.aaa4691","volume":"7","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan S, Mok S, Homet Moreno B, Tsoi J, Robert L, Goedert L, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors inBRAFV600E melanoma. Sci Transl Med. 2015;7(279):241r\u201379r.","journal-title":"Sci Transl Med"},{"issue":"2","key":"8083_CR14","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2217\/imt.15.111","volume":"8","author":"S Valpione","year":"2016","unstructured":"Valpione S, Campana LG. Immunotherapy for advanced melanoma: future directions. Immunotherapy-UK. 2016;8(2):199\u2013209. https:\/\/doi.org\/10.2217\/imt.15.111.","journal-title":"Immunotherapy-UK."},{"key":"8083_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.semcancer.2017.09.004","volume":"52","author":"ML Axelrod","year":"2018","unstructured":"Axelrod ML, Johnson DB, Balko JM. Emerging biomarkers for cancer immunotherapy in melanoma. Semin Cancer Biol. 2018;52:207\u201315. https:\/\/doi.org\/10.1016\/j.semcancer.2017.09.004.","journal-title":"Semin Cancer Biol"},{"issue":"12","key":"8083_CR16","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1001\/jamaoncol.2020.4401","volume":"6","author":"R Dummer","year":"2020","unstructured":"Dummer R, Ascierto PA, Nathan P, Robert C, Schadendorf D. Rationale for immune checkpoint inhibitors plus targeted therapy in metastatic melanoma: a review. Jama Oncol. 2020;6(12):1957. https:\/\/doi.org\/10.1001\/jamaoncol.2020.4401.","journal-title":"Jama Oncol."},{"issue":"3","key":"8083_CR17","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.immuni.2020.07.007","volume":"53","author":"M Effern","year":"2020","unstructured":"Effern M, Glodde N, Braun M, Liebing J, Boll HN, Yong M, et al. Adoptive T cell therapy targeting different gene products reveals diverse and context-dependent immune evasion in melanoma. Immunity. 2020;53(3):564\u201380. https:\/\/doi.org\/10.1016\/j.immuni.2020.07.007.","journal-title":"Immunity."},{"key":"8083_CR18","doi-asserted-by":"crossref","unstructured":"Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope FA. Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. Cancer Discov. 2020;10(12):1808\u201325.","DOI":"10.1158\/2159-8290.CD-20-0522"},{"key":"8083_CR19","doi-asserted-by":"crossref","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer cell. 2021;39(2):154\u201373.","DOI":"10.1016\/j.ccell.2020.10.001"},{"key":"8083_CR20","doi-asserted-by":"publisher","unstructured":"Heydt C, Rehker J, Pappesch R, Buhl T, Ball M, Siebolts U, Haak A, Lohneis P, B\u00fcttner R, Hillmer AM et al. Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing. Sci Rep-UK. 2020; 10(1). doi: https:\/\/doi.org\/10.1038\/s41598-020-68394-4.","DOI":"10.1038\/s41598-020-68394-4"},{"issue":"7","key":"8083_CR21","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1158\/2159-8290.CD-16-1184","volume":"7","author":"D Ajona","year":"2017","unstructured":"Ajona D, Ortiz-Espinosa S, Moreno H, Lozano T, Pajares MJ, Agorreta J, et al. A combined PD-1\/C5a blockade synergistically protects against lung Cancer growth and metastasis. Cancer Discov. 2017;7(7):694\u2013703. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-1184.","journal-title":"Cancer Discov"},{"issue":"7","key":"8083_CR22","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2013.98","volume":"10","author":"M Razzak","year":"2013","unstructured":"Razzak M. Anti-PD-1 approaches\u2014important steps forward in metastatic melanoma. Nat Rev Clin Oncol. 2013;10(7):365. https:\/\/doi.org\/10.1038\/nrclinonc.2013.98.","journal-title":"Nat Rev Clin Oncol"},{"key":"8083_CR23","doi-asserted-by":"publisher","unstructured":"A Set of Transcriptomic Changes Is Associated with Anti\u2013PD-1 Resistance. Cancer Discov. 2016; 6(5):471\u2013472.doi: https:\/\/doi.org\/10.1158\/2159-8290.CD-RW2016-057.","DOI":"10.1158\/2159-8290.CD-RW2016-057"},{"issue":"6411","key":"8083_CR24","doi-asserted-by":"publisher","first-page":"r3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy. Science. 2018;362(6411):r3593.","journal-title":"Science."},{"issue":"1","key":"8083_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, et al. Genomic and Transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165(1):35\u201344. https:\/\/doi.org\/10.1016\/j.cell.2016.02.065.","journal-title":"Cell."},{"issue":"11","key":"8083_CR26","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin D, Assenov Y, Plass C, Koeffler HP. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 2018;28(11):1747\u201356. https:\/\/doi.org\/10.1101\/gr.239244.118.","journal-title":"Genome Res"},{"issue":"7","key":"8083_CR27","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"8083_CR28","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang L, Han Y, He Q. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284\u20137. https:\/\/doi.org\/10.1089\/omi.2011.0118.","journal-title":"OMICS"},{"issue":"43","key":"8083_CR29","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545\u201350. https:\/\/doi.org\/10.1073\/pnas.0506580102.","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"8083_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon A, Birger C, Thorvaldsd\u00f3ttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database Hallmark gene set collection. Cell Syst. 2015;1(6):417\u201325. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004.","journal-title":"Cell Syst"},{"issue":"1","key":"8083_CR31","doi-asserted-by":"publisher","first-page":"180015","DOI":"10.1038\/sdata.2018.15","volume":"5","author":"S Bhattacharya","year":"2018","unstructured":"Bhattacharya S, Dunn P, Thomas CG, Smith B, Schaefer H, Chen J, et al. ImmPort, toward repurposing of open access immunological assay data for translational and clinical research. SCI DATA. 2018;5(1):180015. https:\/\/doi.org\/10.1038\/sdata.2018.15.","journal-title":"SCI DATA"},{"issue":"21","key":"8083_CR32","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","volume":"77","author":"T Li","year":"2017","unstructured":"Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108\u201310. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0307.","journal-title":"Cancer Res"},{"issue":"7","key":"8083_CR33","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","volume":"37","author":"AM Newman","year":"2019","unstructured":"Newman AM, Steen CB, Liu CL, Gentles AJ, Chaudhuri AA, Scherer F, et al. Determining cell type abundance and expression from bulk tissues with digital cytometry. Nat Biotechnol. 2019;37(7):773\u201382. https:\/\/doi.org\/10.1038\/s41587-019-0114-2.","journal-title":"Nat Biotechnol"},{"issue":"6165","key":"8083_CR34","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","volume":"342","author":"J Couzin-Frankel","year":"2013","unstructured":"Couzin-Frankel J. Cancer immunotherapy. Science. 2013;342(6165):1432\u20133. https:\/\/doi.org\/10.1126\/science.342.6165.1432.","journal-title":"Science."},{"issue":"6257","key":"8083_CR35","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, Zimmer L, et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015;350(6257):207\u201311. https:\/\/doi.org\/10.1126\/science.aad0095.","journal-title":"Science."},{"key":"8083_CR36","doi-asserted-by":"publisher","unstructured":"Howitt BE, Shukla SA, Sholl LM, Ritterhouse LL, Watkins JC, Rodig S, Stover E, Strickland KC, D Andrea AD, Wu CJ et al. Association of Polymerase e\u2013mutated and microsatellite-instable endometrial cancers with Neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1. Jama Oncol 2015; 1(9):1319, DOI: https:\/\/doi.org\/10.1001\/jamaoncol.2015.2151.","DOI":"10.1001\/jamaoncol.2015.2151"},{"issue":"20","key":"8083_CR37","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1056\/NEJMc1508163","volume":"373","author":"TA Chan","year":"2015","unstructured":"Chan TA, Wolchok JD, Snyder A. Genetic basis for clinical response to CTLA-4 blockade in melanoma. New Engl J Med. 2015;373(20):1984. https:\/\/doi.org\/10.1056\/NEJMc1508163.","journal-title":"New Engl J Med."},{"issue":"6230","key":"8083_CR38","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1126\/science.aaa1348","volume":"348","author":"NA Rizvi","year":"2015","unstructured":"Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer. Science. 2015;348(6230):124\u20138. https:\/\/doi.org\/10.1126\/science.aaa1348.","journal-title":"Science."},{"issue":"22","key":"8083_CR39","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","volume":"378","author":"MD Hellmann","year":"2018","unstructured":"Hellmann MD, Ciuleanu T, Pluzanski A, Lee JS, Otterson GA, Audigier-Valette C, et al. Nivolumab plus Ipilimumab in lung Cancer with a high tumor mutational burden. New Engl J Med. 2018;378(22):2093\u2013104. https:\/\/doi.org\/10.1056\/NEJMoa1801946.","journal-title":"New Engl J Med"},{"issue":"7749","key":"8083_CR40","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","volume":"567","author":"R Rosenthal","year":"2019","unstructured":"Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, et al. Neoantigen-directed immune escape in lung cancer evolution. Nature. 2019;567(7749):479\u201385. https:\/\/doi.org\/10.1038\/s41586-019-1032-7.","journal-title":"Nature."},{"issue":"12","key":"8083_CR41","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/jnci\/djy060","volume":"110","author":"A Desrichard","year":"2018","unstructured":"Desrichard A, Kuo F, Chowell D, Lee K, Riaz N, Wong RJ, et al. Tobacco smoking-associated alterations in the immune microenvironment of squamous cell carcinomas. J Natl Cancer Institute. 2018;110(12):1386\u201392. https:\/\/doi.org\/10.1093\/jnci\/djy060.","journal-title":"J Natl Cancer Institute"},{"issue":"5","key":"8083_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006773","volume":"13","author":"NJ Fredriksson","year":"2017","unstructured":"Fredriksson NJ, Elliott K, Filges S, Van den Eynden J, St\u00e5hlberg A, Larsson E. Recurrent promoter mutations in melanoma are defined by an extended context-specific mutational signature. PLoS Genet. 2017;13(5):e1006773. https:\/\/doi.org\/10.1371\/journal.pgen.1006773.","journal-title":"PLoS Genet"},{"issue":"6024","key":"8083_CR43","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"RD Schreiber","year":"2011","unstructured":"Schreiber RD, Old LJ, Smyth MJ. Cancer Immunoediting: integrating Immunity's roles in Cancer suppression and promotion. SCIENCE. 2011;331(6024):1565\u201370. https:\/\/doi.org\/10.1126\/science.1203486.","journal-title":"SCIENCE."},{"issue":"5","key":"8083_CR44","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/ni.3693","volume":"18","author":"JC Rieckmann","year":"2017","unstructured":"Rieckmann JC, Geiger R, Hornburg D, Wolf T, Kveler K, Jarrossay D, et al. Social network architecture of human immune cells unveiled by quantitative proteomics. Nat Immunol. 2017;18(5):583\u201393. https:\/\/doi.org\/10.1038\/ni.3693.","journal-title":"Nat Immunol"},{"issue":"1","key":"8083_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/s41392-020-00348-8","volume":"5","author":"Y Cao","year":"2020","unstructured":"Cao Y, Wang X, Jin T, Tian Y, Dai C, Widarma C, et al. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Signal Transduction Targeted Therapy. 2020;5(1):250. https:\/\/doi.org\/10.1038\/s41392-020-00348-8.","journal-title":"Signal Transduction Targeted Therapy"},{"issue":"4","key":"8083_CR46","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/j.jaad.2018.10.062","volume":"80","author":"E Coleman","year":"2019","unstructured":"Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: a single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. J Am Acad Dermatol. 2019;80(4):990\u20137. https:\/\/doi.org\/10.1016\/j.jaad.2018.10.062.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"8083_CR47","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1093\/neuros\/nyy392","volume":"84","author":"J Lynes","year":"2019","unstructured":"Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, et al. Cytokine microdialysis for real-time immune monitoring in glioblastoma patients undergoing checkpoint blockade. Neurosurgery. 2019;84(4):945\u201353. https:\/\/doi.org\/10.1093\/neuros\/nyy392.","journal-title":"Neurosurgery."},{"issue":"6371","key":"8083_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","volume":"359","author":"B Routy","year":"2018","unstructured":"Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daill\u00e8re R, et al. Gut microbiome influences efficacy of PD-1\u2013based immunotherapy against epithelial tumors. Science. 2018;359(6371):91\u20137. https:\/\/doi.org\/10.1126\/science.aan3706.","journal-title":"Science."},{"issue":"6230","key":"8083_CR49","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"TN Schumacher","year":"2015","unstructured":"Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971.","journal-title":"Science."}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08083-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08083-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T08:10:06Z","timestamp":1617955806000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08083-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8083"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08083-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"379"}}